Abstract
Wockhardt pharmaceuticals have developed the novel antibacterial drug, levonadifloxacin (WCK 771); to treat the infections caused by resistant gm +ve bacteria, and subsequently launched into Indian market a year ago with the brand name EMROK. During the scale up of levonadifloxacin seven impurities were identified. Out of seven known process impurities, five impurities were synthesized earlier as reference standards and validated through High-Performance Liquid Chromatography (HPLC). In order to compliment our earlier efforts, the current study describes the establishment of an efficient synthetic routes for remaining two process impurities i.e. impurity 5 and impurity 7 of levonadifloxacin. Here, the syntheses of remaining two impurities are demonstrated in details.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
